EFAVIRENZ FOR CARDIAC RISK DUE TO HIV METABOLIC DISORDER
$0M01FY2000RRNIH
University Of California San Diego, La Jolla CA
Investigators
Linked publications & trials
Paper 38778481Paper 38225212Paper 37046763Paper 36288905Paper 35895672Paper 35668631Paper 35306227Paper 35197258Paper 34928415Paper 34654027Paper 34166655Paper 33388403Paper 33156902Paper 33002231Paper 32954444Paper 32299324Paper 32184195Paper 31818851Paper 31505070Paper 31404238Paper 31161437Paper 31156069Paper 30508411Paper 30487263Paper 30445386Paper 30421439Paper 30354704Paper 30348535Paper 30132040Paper 29605094Paper 29370333Paper 29276107Paper 29271110Paper 29051146Paper 28830083Paper 28754692Paper 28572159Paper 28187771Paper 27600072Paper 27495299Paper 27473350Paper 27448468Paper 27293521Paper 27166718Paper 27142425Paper 27139783Paper 27018723Paper 26798961Paper 26747734Paper 26689571Paper 26666201Paper 26442836Paper 26430087Paper 26378004Paper 26305897Paper 26265126Paper 26091977Paper 26085555Paper 26083739Paper 26081623Paper 26056337Paper 25965871Paper 25903538Paper 25861135Paper 25835440Paper 25817226Paper 25714579Paper 25564368Paper 25481571Paper 25451450Paper 25433211Paper 25313914Paper 25303490Paper 25182189Paper 25102180Paper 25070961Paper 24938585Paper 24888477Paper 24834916Paper 24780043Paper 24755714Paper 24751112Paper 24700865Paper 24657294Paper 24642382Paper 24636844Paper 24615880Paper 24610327Paper 24570214Paper 24436138Paper 24354476Paper 24344872Paper 24269133Paper 24249120Paper 24220913Paper 24206458Paper 24119938Paper 24053522Paper 24033699Paper 24029427
Abstract
Determine if subjects with evidence of metabolic dysregulation who are switched from a protease inhitibor (PI) based highly active antiretroviral therapy (HAART) regimen to an Efavirenz based regimen experience greater improvement in hyperlipidemia, insulin resistance, lipodystrophy, and central adiposity than subjects who continue with a PI based HAART regimen.
View original record on NIH RePORTER →